Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study quantifies how federal and industry sponsorship differ in US cancer clinical trials, highlighting complementary focuses: industry emphasizes single-agent drug therapies, while federal trials prioritize multimodality regimens, rar
This study compares US federally sponsored and industry-sponsored cancer clinical trials, highlighting differences in trial focus, populations, and interventions, and underscoring their complementary roles in advancing oncology research.
This study identifies that 30% of gynecologic cancer clinical trials fail to complete, with insufficient patient accrual as the leading cause, highlighting crucial factors like intervention type, initiation year, and geographic variations t
Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while s